MDNews - Lower Hudson/Bronx

August/September 2020

Issue link: https://viewer.e-digitaledition.com/i/1304029

Contents of this Issue

Navigation

Page 8 of 23

Dr. Hagge-Greenberg says. "Among the novel therapies we offer are the UroLift and the Rezum procedure." In the UroLift for benign prostatic hypertrophy, implants are placed to hold prostate tissue away from the urethra. This can help with many issues from incomplete voiding to urinary incontinence to sexual dysfunction, according to product lit- erature. In the Rezum in-office procedure, hot water vapors are introduced into the prostate, shrinking inflamed prostate tissue and improving urine flow. When it comes to prostate cancer, Dr. Lerner takes credit for performing the greatest number of robotic radical prostatecto- mies in the region. The team, with Dr. Lerner at the helm, has performed more of these surgeries than any other program in Westchester County and the surrounding area. "What separates us from the large academic medical cen- ters in the area is the personalized care we offer our patients," Dr. Lerner says. "We look to see which patients are good candidates for these types of treatments," Dr. Glassman adds. "While we appreciate the benefits of robotic prostatectomies, we first ensure it's the right treatment for the patient." Indeed, patient selection has become one of the key concerns in prostate cancer treatment today. "I think what we're doing with prostate cancer is trying to better define who should be treated and who should not be treated," Dr. Lerner says. "Twenty years ago, we went by the mantra of screening, early detection and early intervention. Now, we realize that a good proportion of men with a new diagnosis may be able to defer treatment for a defined period through the implementation of active surveillance. So while we've maintained a high level of care with regard to treating localized disease, whether with robotic surgery or cutting-edge radiation, we manage upwards of 50% of men with active surveillance, thereby avoiding the potential morbidity of treatment." These men may eventually need treatment, Dr. Lerner adds, and the high standards applied during active surveillance — regular blood work, exams and MRI scans, including, if necessary, MRI- guided biopsies — allow prompt transition to active treatment as needed. "We are looking at cancers at the molecular level," Dr. Lerner says. "We perform genomic testing to further differentiate men with more aggressive cancers from ones that are potentially less aggressive or relatively innocuous. With regards to prostate cancer, we are being more judicious with the applications of targeted screening and more judicious in distinguishing who needs to be treated while maintaining state-of-the-art care for those who do receive robotic surgery or cutting-edge radia- tion therapy." OTHER UROLOGIC CANCERS In addition to prostate cancers, the surgeons at White Plains Hospital offer treatment for cancers of the bladder and kidneys, among others. Widespread imaging has a llowed surgeons to identify kidney tumors earlier, Dr. Lerner says, a llowing the option for sma ller-sca le robotic procedures that preser ve the majority of the kidney. As with prostate ca ncers, some patients with kidney ca ncer ca n be ma naged with sur veil- lance or seria l imaging — regular-interva l imaging to follow a tumor's progress. "There are some patients who can be treated with nonsurgical ablative techniques," Dr. Lerner adds. "It's key to see which people can avoid intervention, while those who need it obtain state-of-the-art care." Bladder cancer is potentially a chronic condition, with upwards of 70% of patients experiencing recurrence, Dr. Lerner says. "We are now using blue-light cystoscopic examinations, which can identify more subtle bladder tumors," he says. "This has been shown to reduce the recurrence rate, and thereby potentially reduce the rate of progression." CARING FOR WOMEN White Plains Hospital runs a robust treatment program for women, too. Dr. Fleischmann is board certified in female pelvic medicine and reconstructive surgery. "I perform robotic surgery to lift bladders and fix prolapse," Dr. Fleischmann says. "I also offer pelvic floor reconstruction and sling procedures for incontinence." She uses the da Vinci robot to perform these surgeries. The newest treatment being used by the team to address urinary incontinence is Bulkamid injections. "It just became FDA approved in January and has been used to treat women in Europe for about 10 years," Dr. Fleischmann says. "It's a minimally invasive procedure — an injection into the opening of the bladder that cushions the insides so women don't leak urine." The bulking agent, which is made up of 97.5% water and 2.5% polyacrylamide, acts as "a scaffold for cells to grow," according to Bulkamid literature. The expert team of surgeons make up the first urology practice to officially join White Plains Hospital Physician Associates. M D N E W S . C O M /// M D N E W S L O W E R H U D S O N / B R O N x ■ 2 0 2 0 0 9

Articles in this issue

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - August/September 2020